Botanix Pharmaceuticals (ASX:BOT) Reports Strong Sofdra™ Launch Performance
Botanix Pharmaceuticals (ASX:BOT) reports $25M AUD in Sofdra™ sales and expansion of prescriber network, signaling strong market performance.
Category: ASX-BOT
Botanix Pharmaceuticals
Botanix Pharmaceuticals (ASX:BOT) Secures A$48M Debt Facility
Botanix Pharmaceuticals (ASX:BOT) secures A$48 million debt facility with Kreos Capital to support Sofdra™ commercialisation and platform expansion.